Feasibility and Safety of IMP321 (Eftilagimod Alpha) for Advanced Stage Solid Tumors | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Feasibility and Safety of IMP321 (Eftilagimod Alpha) for Advanced Stage Solid Tumors	Abdominal Neoplasms, Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Peritoneal Diseases, carcinoma, epithelial neoplasm, neoplasm, peritoneal neoplasm, transitional cell carcinoma, urothelial carcinoma	Active, not recruiting	Phase 1	2026-02-19		NCT03252938

2 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Immutep S.A.S.	4
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest	34

12 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Agaplesion Markus Krankenhaus Frankfurter Diakonie Kliniken gGmbH	Frankfurt	Germany	1
Helios Dr. Horst Schmidt Klinikum Wiesbaden	Wiesbaden	Germany	1
Helios Klinikum Bad Saarow	Bad Saarow	Germany	15
Hämatologisch Onkologische Praxis Eppendorf (HOPE)	Hamburg	Germany	3
Kliniken der Stadt Köln gGmbH, Studienzentrum der Lungenklinik, Krankenhaus Merheim	Cologne	Germany	1
Krankenhaus Nordwest	Frankfurt	Germany	7
Marienhospital Herne, Klinik der Ruhr Universität Bochum, Klinik für Urologie	Herne	Germany	1
Universität Gießen und Marburg GmbH	Giessen	Germany	1
Universitätsklinikum Essen	Essen	Germany	39
Universitätsklinikum Tübingen	Tübingen	Germany	57
Universitätsklinikum Ulm, Early Clinical Trials Unit (ECTU)	Ulm	Germany	1
Universitätsmedizin der Johannes Gutenberg-Universität Mainz	Mainz	Germany	23